BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rullman E, Melin M, Mandić M, Gonon A, Fernandez-Gonzalo R, Gustafsson T. Circulatory factors associated with function and prognosis in patients with severe heart failure. Clin Res Cardiol 2020;109:655-72. [PMID: 31562542 DOI: 10.1007/s00392-019-01554-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Olsson K, Cheng AJ, Al‐ameri M, Tardif N, Melin M, Rooyackers O, Lanner JT, Westerblad H, Gustafsson T, Bruton JD, Rullman E. Sphingomyelinase activity promotes atrophy and attenuates force in human muscle fibres and is elevated in heart failure patients. J cachexia sarcopenia muscle. [DOI: 10.1002/jcsm.13029] [Reference Citation Analysis]
2 Hu Z, Wang J, Xue Y, Zhang Q, Xu Q, Ji K, Yin R. The Neutrophil-to-Albumin Ratio as a New Predictor of All-Cause Mortality in Patients with Heart Failure. JIR 2022;Volume 15:701-13. [DOI: 10.2147/jir.s349996] [Reference Citation Analysis]
3 May BM, Kochi AN, Magalhães APA, Scolari F, Zimerman A, Andrades M, Zimerman LI, Rohde LE, Pimentel M. Growth/differentiation factor-15 (GDF-15) as a predictor of serious arrhythmic events in patients with nonischemic dilated cardiomyopathy. J Electrocardiol 2021;70:19-23. [PMID: 34839084 DOI: 10.1016/j.jelectrocard.2021.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Tokavanich N, Sinphurmsukskul S, Kongruttanachok N, Thammanatsakul K, Sritangsirikul S, Ariyachaipanich A, Ongcharit P, Siwamogsatham S, Boonyaratavej S, Puwanant S. Circulating growth differentiation factor-15 as a novel biomarker in heart transplant. ESC Heart Fail 2021;8:3279-85. [PMID: 34110100 DOI: 10.1002/ehf2.13471] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 May BM, Pimentel M, Zimerman LI, Rohde LE. GDF-15 as a Biomarker in Cardiovascular Disease. Arq Bras Cardiol 2021;116:494-500. [PMID: 33566936 DOI: 10.36660/abc.20200426] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Huo S, Shi W, Ma H, Yan D, Luo P, Guo J, Li C, Lin J, Zhang C, Li S, Lv J, Lin L. Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene. Oxid Med Cell Longev 2021;2021:6699054. [PMID: 33824698 DOI: 10.1155/2021/6699054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mörth C, Sabaa AA, Freyhult E, Christersson C, Hashemi J, Hashemi N, Kamali-Moghaddam M, Molin D, Höglund M, Eriksson A, Enblad G. Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma. Cardiooncology 2021;7:6. [PMID: 33536059 DOI: 10.1186/s40959-021-00092-0] [Reference Citation Analysis]
8 Wu Y, Pan N, An Y, Xu M, Tan L, Zhang L. Diagnostic and Prognostic Biomarkers for Myocardial Infarction. Front Cardiovasc Med 2020;7:617277. [PMID: 33614740 DOI: 10.3389/fcvm.2020.617277] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Cho J, Choi Y, Sajgalik P, No MH, Lee SH, Kim S, Heo JW, Cho EJ, Chang E, Kang JH, Kwak HB, Park DH. Exercise as a Therapeutic Strategy for Sarcopenia in Heart Failure: Insights into Underlying Mechanisms. Cells 2020;9:E2284. [PMID: 33066240 DOI: 10.3390/cells9102284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
10 Sultan A, Wörmann J, Lüker J, V D Bruck J-, Plenge T, Rudolph V, Klinke A, Heijman J, Mollenhauer M, Ravekes T, Baldus S, Steven D. Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response. Clin Res Cardiol 2021;110:1173-80. [PMID: 32564144 DOI: 10.1007/s00392-020-01690-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Brandenburg V, Heine GH, Marx N, Stöhr R. Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage. Clin Res Cardiol 2020;109:1316-8. [PMID: 32215701 DOI: 10.1007/s00392-020-01630-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Thorén E, Wernroth ML, Christersson C, Grinnemo KH, Jidéus L, Ståhle E. Compared with matched controls, patients with postoperative atrial fibrillation (POAF) have increased long-term AF after CABG, and POAF is further associated with increased ischemic stroke, heart failure and mortality even after adjustment for AF. Clin Res Cardiol 2020;109:1232-42. [PMID: 32036429 DOI: 10.1007/s00392-020-01614-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]